Marinomed Biotech AG: Restructuring proceedings successfully completed
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
Ad-hoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Lucia Ziegler, MSc
Head of Investor & Public Relations